Upifitamab rilsodotin is a monoclonal antibody conjugated commercialized by Mersana Therapeutics, with a leading Phase III program in Ovarian Cancer. According to Globaldata, it is involved in 3 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Upifitamab rilsodotin’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Upifitamab rilsodotin is expected to reach an annual total of $268 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Upifitamab rilsodotin Overview

Upifitamab rilsodotin is under development for the treatment of solid tumors including non-small cell lung cancer, high-grade serous epithelial ovarian, fallopian tube cancer, peritoneal cancer and platinum-sensitive ovarian cancer. The drug candidate is an anti-NaPi2b immunoconjugate comprises auristatin molecules conjugated to a humanized anti-NaPi2b monoclonal antibody XMT-1535. It is administered through intravenous infusion. The drug candidate is developed based on dolaflexin antibody drug conjugate technology.

It was under development for the treatment of thyroid carcinoma, papillary renal cell carcinoma, endometrial cancer, salivary duct carcinoma.

Mersana Therapeutics Overview

Mersana Therapeutics (Mersana) is a pharmaceutical company. It develops antibody-drug conjugates (ADC) for the treatment of cancer. The company’s pipeline product XMT-1660, XMT-2056, XMT-2068, and XMT-2175 an ADC which targets sodium-dependent phosphate transport protein NaPi2b utilizing Dolaflexin platform. Mersana utilizes various technologies including DolaLock Technology, Dolaflexin, Dolasynthen, and Immunosynthen in developing ADCs. Its products also include ASN004 which is in dose escalation stage. The company develops immunoconjugates to deliver payloads of anti-tumor agents directly to cancerous cells. Its products are used to treat multiple cancer indications including gastric cancer and metastatic breast cancer. Mersana is headquartered in Cambridge, Massachusetts, the US.

The operating loss of the company was US$168.9 million in FY2021, compared to an operating loss of US$88.1 million in FY2020. The net loss of the company was US$170.1 million in FY2021, compared to a net loss of US$88.1 million in FY2020. The company reported revenues of US$5.6 million for the third quarter ended September 2022, an increase of 30.1% over the previous quarter.

For a complete picture of Upifitamab rilsodotin’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.